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Patient 1. A 30-year-old woman had had type-I (insulin-dependent)
diabetes mellitus (IDDM) for 27 years. At the time of evaluation, she
weighed 50 kg, was 157 cm tall, and had a blood pressure of 114/80 mm
Hg. She had background retinopathy and no clinical neuropathy. Her
urine was positive for protein by dipstick and the albumin excretion rate
was 2500 /tg/min. Her hemoglobin A1 was 8.9%; serum creatinine, 1.2
mg/dl; and creatinine clearance, 79 mI/mm/i .73 m2. As part of the study
of renal structure and function in siblings concordant for IDDM, she
underwent a percutaneous renal biopsy.
Light microscopy revealed that 30% of the glomeruli were globally
sclerosed. The others all had moderately severe diffuse mesangial
expansion. Many afferent and efferent glomerular arterioles showed
varying amounts of hyalinosis, with some vessel walls completely
replaced by the waxy, homogeneous, pink hyaline material. Mild
diffuse interstitial expansion was evident, and patchy areas of more
marked interstitial fibrosis were found, mainly in association with
atrophic tubules or sclerotic glomeruli. Electron microscopic morpho-
metric analysis showed the mesangial volume fraction (that is, fraction
of glomerular volume occupied by mesangium [VvMesJ) to be 0.40
(upper limit of normal, 0.22). The VvMes cells measured 0.11 and
VvMes matrix 0.26; the ratio of mesangial matrix to total mesangium
was 0.65 (normal ratio 0.5). The surface density of the peripheral
glomerular basement membrane (that is, the filtration surface per unit of
tuft area {SvPGBM]) was 0.087 (lower limit of normal, 0.095) and the
GBM width was 661 nm (upper limit of normal, 450 nm).
Patient 2. The 28-year-old sister of Patient 1 developed IDDM at age
5. She had no retinopathy or neuropathy. She weighed 60 kg, was 164
cm tall, and had a blood pressure of 102/64 mm Hg. The urine was
negative for protein by dipstick; urine albumin excretion rate was 75
g/min. Her hemoglobin A1 was 14%; serum creatinine, 0.9 mg/dl; and
creatinine clearance, 71 ml/min/l .73 m2.
Light microscopic evaluation of her renal biopsy specimen was
similar to that of her sister. Morphometric analysis revealed a VvMes of
0.45, a ratio of mesangial matrix to total mesangium of 0.63, an
SvPGBM of 0.83, and a GBM width of 712 nm.
Discussion
DR. S. MICHAEL MAUER (Co-Director, Pediatric Nephrol-
ogy, Department of Pediatrics, and Professor of Pediatrics,
University of Minnesota Medical School, Minneapolis, Minne-
sota): Diabetic nephropathy represents the single most impor-
tant cause of renal failure in adults in the Western world and is
responsible for 25% of all new cases of uremia [1]. Overall,
approximately 35% to 45% of patients with long-standing insu-
lin-dependent diabetes mellitus (IDDM) ultimately will develop
nephropathy, defined as dipstick-positive proteinuria, hyper-
tension, and falling GFR [2]. The peak incidence for the
development of clinical renal disease occurs after about 16
years of IDDM but does not reach zero even after 40 years [2].
Patients with diabetic nephropathy account for virtually all the
increased mortality associated with type-I diabetes [2]; those
who escape nephropathy have a mortality rate that differs little
from that of the nondiabetic population [2]. It is clear that
clinical diabetic nephropathy is the consequence of the ad-
vanced development of a constellation of specific lesions unique
to the diabetic state. These advanced lesions represent the final
stages in a continuum of progression of renal structural abnor-
malities. Animal and human studies support the general concept
that the factors involved in the genesis of the early structural
consequence of renal injury might be different from the factors
driving the progression of advanced renal structural changes; in
this Forum, I will focus primarily on the earlier aspects of
diabetic nephropathy, because an understanding of these
phases of the natural history of this disorder (genesis) is more
likely to promote the development of specific prevention strat-
egies than is knowledge about the later stages of the disease
(progression). In addition, I will attempt to develop the concept
of susceptibility to diabetic nephropathy; the lack of uniformity
in the renal structural response to the diabetic state appears to
represent a critical variable determining the development of
serious diabetic renal disease.
Presentation of this Forum is made possible by grants from Merck
Sharp & Dohme International; Dialysis Clinic, Incorporated; Marion
Merrell Dow, Incorporated; and Mead-Johnson Pharmaceuticals.
© 1994 by the International Society of Nephrology
Pathologic findings
The early pioneering work of Østerby demonstrated that the
glomerulus, measured morphometrically, is enlarged to some
degree at the onset of IDDM but otherwise appears normal [3].
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Our studies of identical twins discordant for IDDM confirmed
this finding [41. In these latter studies the nondiabetic twins,
presumably identical to their twins with IDDM except for the
presence of diabetes, all had normal glomerular structure. Thus
the diabetic state itself, rather than some independent factor(s),
appears to be a prerequisite for the expression of diabetic
glomerulopathy. Østerby demonstrated that GBM thickening
can be detected 2 years after the onset of IDDM; mesangial
expansion can be quantitated after 3.5 to 5 years of diabetes [3].
Ultimately, in patients developing serious renal disease, the
dominant pathologic process is most often diffuse mesangial
expansion [5, 6]. The Kimmeistiel-Wilson nodular lesion is the
most marked expression of pathologic mesangial expansion in
diabetes. While specific for diabetes, only a minority of patients
who develop overt diabetic nephropathy have nodular glomer-
ulosclerosis [7].
Other common lesions in the kidney of patients with diabetes
include afferent and efferent glomerular arteriolar hyalinosis
and exudative hyaline lesions (fibrin caps) in the subendothelial
space and under the parietal layer of the epithelium along
Bowman's capsule (capsular drops) [8]. The latter might be
consequent to the adhesions of tufts containing capsular drops
to the parietal layer of glomerular epithelium, followed by GBM
rupture, extrusion of the fibrin cap, and subsequent retraction
and remodeling of the glomerular tuft. The hyaline lesions in the
glomerular arterioles can be among the earliest renal changes in
IDDM and could be important in promoting glomerular scarring
[9]. Capillary loops can sometimes develop microaneurysms,
which appear to be the forerunners of Kimmeistiel-Wilson
nodules [10]. Epithelial and endothelial cell structures are
generally well preserved until late in the course of nephropathy
[11, 12]. Diffuse interstitial expansion can occur early in dia-
betic nephropathy [5, 13], but advanced tubulointerstitial
changes are seen primarily as the disease progresses to its later
stages [5, 141.
Structural-functional relationships
Accurate morphometric techniques have allowed quantita-
tion of the structural changes of diabetic nephropathy [15, 16].
This has facilitated correlation of these changes with renal
function.
Glomerular and tubular basement membranes. Measurement
of GBM width using precise approaches such as the orthogonal
intercept method [15] demonstrate thickening in almost all
patients with long-standing IDDM [3, 5, 17]. In identical twins
discordant for IDDM, GBM width is always greater in the
diabetic twin, even if still in the normal range (Fig. 1). This
thickening, detectable after 2 years of diabetes [3, 7], is gener-
ally uniform both within and between glomeruli, and primarily
involves the lamina densa. Initial immunofluorescent studies by
Falk et a! that showed increased staining for normal GBM
constituents [18] suggest that increased production, decreased
turnover, or both result in the accumulation of GBM material.
More recent studies by Kim et a! showed that some GBM
constituents, such as the cs3(IV)NC and a4(IV)NC domains of
type-IV collagen, have normal or increased staining intensity
along the central aspect of the GBM that persists into advanced
stages of the disease, but cd(IV) and a2(IV)NC domains of
type-TV collagen are decreased in staining intensity along the
inner (endothelial) aspect of the GBM [19]. These studies
Fig. 1. Glomerular (GBM) and tubular basement membrane (TBM)
widths in nondiabetic (S) and type-I diabetic (0) identical twins. Twin
pairs are connected by lines. Note that the GBM width of nondiabetic
twin is always in normal range (shaded areas) and, whether in the
normal range or above, that of the diabetic twin is always greater than
that of the nondiabetic twin. The same is true of TBM width, but normal
values are not yet established. (From Ref. 4.)
confirm the structural heterogeneity of the GBM and indicate
that changes in extracellular matrix (ECM) that occur in dia-
betic nephropathy are highly site specific. Preliminary quanti-
tative immunogold electron microscopic studies by Zhu and
coworkers describe decreased density of type-IV collagen in
the al(IV) and a2(IV)NC domain distribution along the inner
(endothelial) aspects of the GBM in patients with more ad-
vanced lesions [20]; this work confirms the immunofluorescent
microscopy observations. Mesangial matrix density also tended
to be decreased. Makino and colleagues, using scanning elec-
tron microscopy, showed mesangial interposition in advanced
diabetic nephropathy, and offer a possible explanation for the
decrease in al(IV) and a2(IV) staining at both the mesangial
and GBM sites in advanced disease [211. Vernier et a! found
that histochemically identified subepithelial GBM charge-site
density, corresponding to heparan sulfate proteoglycan, was
reduced in more advanced cases of proteinuric diabetic patients
but was normal at the earlier stages and with the milder lesions
of normo- or microalbuminuric patients [221. Makino et a! also
found decreased heparan sulfate staining by immunogold elec-
tron microscopy in advanced cases of diabetic nephropathy
[21]. In parallel, epithelial cell structure measured either as foot
process width or as the more sensitive parameter of filtration
slit-length density is normal in patients with IDDM until high-
level microalbuminuria or overt proteinuria is present [23]. In
other words, only when advanced structural changes of diabe-
tes, including GBM and mesangial expansion, are present are
the earliest epithelial cell structural changes detectable [23].
In summary, early GBM thickening is not associated with
specific or yet-identified ECM compositional changes, but late
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lesions are associated with increases in some and decreases in
other ECM components. Thus these late changes might more
closely relate to the progression as opposed to the genesis of
the earlier GBM widening.
In diabetic patients, immunofluorescence microscopy dis-
closes increased localization of plasma proteins in GBM as well
as in other renal basement membranes, including tubular base-
ment membranes (TBM) and Bowman's capsule [24, 25]. Evi-
dence suggests that this increased localization is related t the
charge of the circulating molecules, as anionic proteins bind
preferentially. This binding is relatively irreversible, however,
and requires harsh treatment with acids to release the bound
protein [25]. Binding of these proteins could relate to decreased
net negative charge of the GBM, perhaps secondary to de-
creased heparan sulfate content.
The GBM width correlates relatively poorly with mesangial
volume fraction and with the functional parameters of GFR and
hypertension [5]. However, GBM width correlates better with
urinary albumin excretion (UAE) [5] and with lamina rara
externa charge-site density [221 (Fig. 2); thus GBM width might
be interrelated with alterations in glomerular permselectivity in
diabetes. The pathogenesis of this relationship is not known.
Because it can be precisely measured, increased GBM width
is a sensitive marker of the diabetic state [3, 8, 171. As I
mentioned, in pairs of identical twins discordant for 10DM,
only diabetic twins showed GBM thickening; thus the diabetic
state is a prerequisite for expression of this abnormality [4].
Tubular basement membrane width also is increased in patients
with IDDM [4]. This finding suggests that pressures and flows in
the glomerular capillaries (normally much higher than those
present in peritubular capillaries) are not prerequisites for the
development of renal basement membrane thickening in IDDM.
Mesangium. Shortly after the onset of IDDM, the fraction of
the glomerular tuft occupied by mesangium is normal, with
roughly equal proportions of cells and matrix. Mter 2 to 3
years, matrix begins to accumulate [12, 261, and mesangial
expansion out of proportion to any increase in glomerular
volume (increased mesangial volume fraction or VvMes) be-
comes quite marked after 10 to 30 years of diabetes in those
patients destined to develop clinical diabetic renal disease [5].
Approximately two-thirds of this mesangial expansion is due to
matrix accumulation [27] and, initially, the expanding me-
sangium appears to contain increased amounts of the usual
mesangial extracellular matrix antigens [18]. In contrast, ad-
vanced mesangial expansion (diffuse glomerulosclerosis) is as-
sociated with decreased intensity of al(IV) and a2(IV)NC
domain [19] and decreased merosin (a laminin-like molecule)
staining intensity (Kim Y, personal communication). Further,
advanced expansion is accompanied by increasing deposition of
scar collagens (types I and II). Even in relatively early lesions,
however, there might already be a subtle decrease in the density
of the classical collagen chains in mesangial matrix, as assessed
by quantitative immunogold electron microscopy [20]. As these
findings indicate, the nature of the ECM molecules that accu-
mulate during the development of diabetic nephropathy lesions
is not well understood.
Approximately one-third of mesangial expansion in diabetes
is due to cellular expansion. Normal mesangial cell antigens,
including smooth muscle antigens, are initially increased in
immunofluorescent staining intensity [28]. It is unclear whether
mesangial cell number, cell size, or both are increased at the
various stages of diabetic nephropathy. Although the total
number of cell nuclei per glomerulus is increased [29], glomeruli
tend to be larger in diabetic patients, and this increase in cell
nuclei per glomerulus could be proportional to that enlarge-
ment. Also, pathologists using light or electron microscopic
routine sectioning strategies tend to overestimate the number of
mesangial cells by misclassifying endothelial cells as mesangial.
Thus, although mesangial cell proliferation is a possibility in
diabetes, it is far from proven. Despite the frequent acceptance
of this possibility as an established fact, the appropriate studies
to determine whether mesangial cell proliferation actually oc-
curs in diabetes have not been done. Most of the mesangial
expansion occurring in diabetes is due to an increase in relative
and absolute mesangial matrix volume [27]. In fact, the propor-
tion of the mesangium that is matrix is increased even in
patients with IDDM whose mesangial volume fraction is in the
normal range [271 (Fig. 3).
The mesangium and glomerular filtration rate (GFR). Mesan-
gial expansion is closely associated with renal function in
diabetic nephropathy [5]. A strong inverse correlation exists
between mesangial volume fraction and GFR. This relationship
probably results from the expanding mesangium compromising
the structure of contiguous glomerular capillaries. We define
glomerular filtration surface as the trilaminar GBM, endothelial
cell, and epithelial cell interface, with no intervening me-
sangium. As the relative volume of the glomerulus occupied by
mesangium increases, the relative peripheral capillary wall
filtration surface decreases (Fig. 4). Substantial support for this
concept comes from the work of Ellis et al [30], confirmed by
Østerby and coworkers [311, showing that peripheral capillary
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Fig. 2. Relationship of charge-site density in lamina rara externa
(LRE) and GBM width in type-I diabetic patients. (From Ref. 22.)
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Fig. 3. Ratio of mesangial matrix to total mesangial volume (matrix
and cell) to mesangial volume fraction (Vv) in type-I diabetic patients.
The normal ratio is 0.5. Note that almost all diabetic patients are above
this value regardless of whether or not mesangium Vv is increased
(above 0.22). (From Ref. 27.)
filtration surface per glomerulus is directly related to GFR (Fig.
5).
The mesangium and hypertension. Virtually all patients with
marked mesangial expansion (specifically, a mesangial volume
fraction > 37%, when mesangium is defined excluding mesan-
gial GBM) have overt proteinuria. Seventy-five percent of the
patients with these advanced mesangial lesions have hyperten-
sion [5], but as Patient I illustrates, 25% are normotensive.
Severe mesangial expansion is thus closely associated with all
the manifestations of overt nephropathy, decreased GFR, pro-
teinuria, and hypertension.
As I noted, 25% of patients with overt nephropathy and
marked mesangial expansion do not have hypertension. Fur-
ther, hypertension can occur in patients with IDDM who have
lesser degrees of mesangial expansion. Hypertension in a
patient with IDDM is most frequently associated with increased
urinary albumin excretion (UAE) and well-established glomer-
ular lesions. Hypertension does not appear to be more common
than in the general population in patients with IDDM who do
not have other structural or functional features of advanced
diabetic nephropathy.
The mesangium and proteinuria. How is albuminuria related
to the structural lesions of diabetic nephropathy? Using mesan-
gial expansion as the key structural parameter [5, 6], we found
that patients with long-standing IDDM and entirely normal
renal function (as indicated by normal UAE, GFR, and blood
pressure) have mesangial volume fractions ranging from normal
to levels bordering on those regularly associated with overt
nephropathy (Group 1 in Fig. 6) [32]. Patients with microalbu-
minuria (increased UAE but below detectability by dipstick),
normal GFR, and normal blood pressure (UAE usually <45
mg!24 hrs or 30 g/min) have mesangial volume fractions
completely overlapping with those in patients whose renal
function is normal (Group 2 in Fig. 6) [32]. Patients with IDDM
who have microalbuminuria and either hypertension, decreased
GFR, or both (UAE usually >45 mg124 hrs) have more ad-
vanced mesangial expansion (Group 3 in Fig. 6) [32]. Values for
UAE between the upper limit of normal (22 mg/24 hr or 15
g/min) and 45 mg!24 hr (30 g/min) do not always predict the
later development of overt nephropathy. Thus normal UAE
does not preclude the presence of important lesions, while
microalbuminuria in the lower ranges does not necessarily
predict structural abnormalities. However, if other manifesta-
tions of overt nephropathy, including hypertension or de-
creased GFR, are present, microalbuminuria is usually in the
higher ranges and generally indicates more advanced structural
injury [32]. This relationship is well illustrated by today's
second patient; she had microalbuminuria (UAE of 108 mg/24
hr or 75 sg/min), reduced GFR, and advanced glomerular
lesions.
In summary, microalbuminuria in the range regularly "pre-
dictive" of the later development of proteinuria is, in fact, a
marker of well-established diabetic glomerulopathy [32, 33].
Nonetheless, measurement of UAE is the most reliable test
available for identifying patients at high risk of progression to
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Fig. 6. Volume fraction of the mesangium (VvMes) in the study
groups. The shaded area represents the mean 2 SD in normal
subjects. The broken line represents the level above which overt
nephropathy regularly occurs (Group Ill vs. Group I, two-tailed P =
0.002; Group III vs. Group II, two-tailed P = 0.007 by Mann-Whitney
U test). Most patients in Group II had UAE <45 mg/24 hr (30 sglmin);
most in Group III had UAE > 45 mg/24 hr. (From Ref. 32.)
overt nephropathy at a time when the disease might still be
amenable to therapeutic intervention.
Glomerular arterioles. Hyaline degenerative changes can
involve both the afferent and efferent glomerular arterioles in
diabetes. This involvement ranges in severity from small
amounts of PAS-positive translucent material under the elastic
membrane of the arterioles to virtually complete replacement of
the smooth muscle of the vessels by this material. Hyaline in
these vessel walls, along the parietal layer of Bowman's capsule
(capsular drop), and in the glomerular subendothelial space
(fibrin cap), appears to contain the same materials: immunoglo-
bulins, fibrinogen, and complement, as well as other plasma
proteins [34]. The pathogenesis of these lesions is unknown. We
recently found that the frequency of the more advanced gb-
merular arteriolar lesions, defined as complete replacement of
smooth muscle cells by hyaline, correlated directly with greater
numbers of globally sclerotic glomeruli; this relationship is
illustrated by the patients presented here [91. This observation
supports the hypothesis that global glomerular sclerosis in
diabetic nephropathy might derive in part from vascular pathol-
ogy. This view is suggested by studies indicating that the
cortical distribution of global glomerular sclerosis in patients
with IDDM fits a pattern consistent with a vasculo-occlusive
process. An additional mechanism of glomerular sclerosis in
diabetes might be extreme mesangial expansion with conse-
quent capillary closure [29].
Interstitium. Interstitial fibrosis is a concomitant of diabetic
nephropathy. Bader and colleagues showed an inverse relation-
ship between morphometric measures of the severity of inter-
stitial fibrosis and GFR [131. In our studies of structural-
functional relationships, we found a significant correlation among
several structural variables, including mesangial volume fraction,
arteriolar hyalinosis, percentage of glomerular sclerosis, and cor-
tical interstitial volume fraction [35]. All four variables correlated
with GFR and UAE. Mesangial volume fraction and cortical
interstitial volume fraction were each partially independent vari-
ables relating to these functional parameters.
Susceptibility
The patients presented today illustrate one of the central
themes of this Forum. Both these siblings, the first with overt
proteinuria and the second with microalbuminuria, have ad-
vanced diabetic nephropathology, including light microscopic
findings of arteriolar hyalinosis, global glomeruloscierosis, and
interstitial expansion, as well as electron microscopic morpho-
metric findings of similarly increased GBM width and increased
mesangial volume fraction, and decreased filtration surface
density. Thus these sisters have remarkable concordance of
glomerular, vascular, and tubulointerstitial lesions of diabetes.
Evidence is developing to support the view that the rate of
progression of the lesions of diabetic nephropathy that are
critical in determining clinical outcome is only partially deter-
mined by glycemic control, and is highly influenced by suscep-
tibility factors that might be genetic, environmental, or both.
Along these lines Seaquist et al examined nephropathy risk in
IDDM multiplex families (in which more than one sibling has
diabetes). The proband (the first of the siblings to develop
diabetes) had a duration of diabetes of at least 10 years and the
sibling a duration of at least 7 years [36]. Of the siblings of
probands free of diabetic nephropathy, 17% had a UAE above
45 mg124 hr (30 gImin). In contrast, 82% of the siblings of
probands with end-stage renal disease had end-stage renal
disease or a UAE above 45 mg/24 hr, and only 17% were
normal.
Borch-Johnsen and colleagues found a higher prevalence of
overt nephropathy in siblings of probands with nephropathy
(33%) than in siblings of normoalbuminuric probands (10%;
P < 0.04) [37]. Both studies were unable to separate genetic
susceptibility from similarities due to shared environment. In
the latter study, hemoglobin A1C loosely but significantly
correlated in the probands and siblings, but environmental and
genetic factors that could potentially affect glycemic control
could not be isolated.
These studies of familial predisposition to renal disease in
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patients with IDDM are supported by observations in two
generations of Pima Indians with type-Il (non-insulin-depen-
dent) diabetes mellitus (NIDDM) [381. In these studies, after
adjustment for other risk factors, proteinuria occurred among
14% of the offspring if neither parent had proteinuria, in 23% if
at least one parent had proteinuria, and in 46% if both parents
had diabetes and proteinuria. Preliminary studies by Fioretto et
al, from which the two patients presented here were taken [39],
indicate that among IDDM sibling pairs, the concordance in
nephropathy incidence is probably based on a concordance in
nephropathic lesions. These ongoing studies reveal less vari-
ance between siblings than among all patients for structural
parameters, including GBM width and mesangial fractional
volume. Thus, after correction for duration of IDDM, the effect
of sibship on lesions was still significant [39]. These data show
that the strong familial concordance for nephropathy risk oper-
ates through a concordance in nephropathic lesions, but these
studies do not determine whether this shared risk is due to
common genetic or environmental influences.
The risk of diabetic nephropathy among Israeli Jews of
non-Ashkenazi origin is higher than that in Ashkenazi Jews
[40]. This 1991 study showed that glycemic control and lower
socioeconomic status significantly and independently corre-
lated with albuminuria. However, even after the authors ad-
justed for these variables, patients of non-Ashkenazi origin still
had an almost threefold greater risk of microalbuminuria. Also,
the odds ratio for risk of nephropathy increased as the quartile
of glycemic control worsened [40]; risk factors for nephropathy
that might be inherited thus might be far more likely to be
expressed in patients with poor glycemic control and low
socioeconomic status. A similar point was made by Krolewski
et al, who suggested that the increased risk for diabetic ne-
phropathy in patients with a genetic background of essential
hypertension was most clearly expressed in patients with poor
glycemic control [41].
If a familial and ethnic propensity to diabetic nephropathy is
partly based on genetic risk factors, then a search for candidate
genes is logical. Such efforts have begun. Some authors [41, 42]
but not all [43] have found that parents of diabetic offspring with
nephropathy have higher levels of arterial blood pressure than
do parents whose diabetic offspring do not have diabetic
nephropathy. Familial clustering of cardiovascular disease oc-
curs in diabetic patients with nephropathy. Cardiovascular
disease was twice as common a cause of death among parents of
diabetic patients with nephropathy than among parents of
diabetic patients without nephropathy. Among diabetics with
nephropathy, those who had a cardiovascular event were 6
times more likely to have a familial history of cardiovascular
disease than were those who had no such event [441.
Hypertension has been implicated in the natural history of
both cardiovascular and renal disease of diabetes mellitus. The
level of activity of the red blood cell sodium/lithium counter-
transport system (Na/LP CTT) has a high degree of heritabil-
ity [451. Increased Na/Li CTT activity is associated with an
increase in blood pressure [46]. Two independent studies found
that the activity of this cation exchanger was elevated in
insulin-dependent diabetic patients with diabetic nephropathy
[41, 47]. Another study found that although the Na/Li CTT
activity was higher in diabetic patients, no difference existed
between those with and without nephropathy [48]. A study in
England found that red cell Na/Li CTT was elevated in
parents whose diabetic offspring had nephropathy compared
with parents whose diabetic offspring had escaped this compli-
cation [49]. This finding was not confirmed in a Danish study,
however [43]. The question of whether genes regulating red cell
Na/Li Cr1' can confer risk of, or protection from, diabetic
nephropathy has not yet been answered.
Red blood cell Na/Li CTF activity has similarities with a
physiologic ubiquitous cation exchanger—the sodium/hydrogen
antiport (Na/H). This cell membrane exchanger is involved
in the regulation of intracellular pH, cell volume and growth,
and sodium reabsorption in the proximal renal tubule [50—52].
Increased Na/H antiport activity has been described in
leukocytes and red blood cells from humans with either essen-
tial hypertension [53] or diabetic nephropathy [54]. Also, in
studies of cultured skin fibroblasts from patients with IDDM,
Na/H antiport activity was increased in those with nephrop-
athy compared with those without nephropathy [55—57]. Cur-
rent evidence suggests that Na/H exchange is mediated by
different Na/H exchanger subtypes and that the same sub-
type of amiloride-sensitive exchanger (NHE-1) can be found in
fibroblasts, in mesangial cells, and in the basolateral site of
renal tubular epithelial cells [58, 59]. Thus, changes in mem-
brane cation transport can be present in a variety of cell types
in patients with diabetic nephropathy. A clear genetic link
between increased Na/H antiport activity and diabetic ne-
phropathy risk is far from established, however. Extracellular
matrix molecules such as fibronectin can interact with integrins
to activate fibroblast Na/H antiport activity [60], so it is
conceivable that the abnormalities of this cation transporter in
cultured skin fibroblasts of patients with IDDM and nephropa-
thy are secondary to other cellular perturbations.
Doria and colleagues presented preliminary data suggesting
that insulin receptor gene polymorphism is associated with
nephropathy risk [611, but that patients with microalbuminuna
and overt proteinuria depart from Hardy-Weinberg equilibrium
in opposite directions [611. Although these interesting prelimi-
nary data require confirmation, they do illustrate the potential
power of molecular biology in unraveling the genetics of sus-
ceptibility to diabetic nephropathy.
It is also noteworthy that the siblings presented here evi-
denced discordance between the severity of the renal, ocular,
and neurologic complications of diabetes. Although frequently
concordant, such discordant cases make it clear that pathoge-
netic factors specific to the organs at risk of diabetic complica-
tions must be operative. In summary, these two sisters with
IDDM illustrate the constellation of the specific and unique
lesions that represent diabetic nephropathology and depict the
interrelationships of renal pathology and function in this dis-
ease. They also exemplify the growing interest in unraveling the
genetic mechanisms that might be important in the pathogenesis
of this disorder.
Questions and answers
Da. NICOLAOS E. MADIAS (Chief, Division of Nephrology,
New England Medical Center, Boston, Massachusetts): Would
you please speculate on what role glycemia might play in the
genesis of the pathologic abnormalities of diabetic nephropa-
thy?
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DR. MAUER: The advanced structural abnormalities of dia-
betic nephropathy seem to require an increase in glucose to be
manifested. A few convincing cases in the literature suggest
that the abnormalities in glycemia required to produce these
lesions are very subtle [621. We've all heard about, read about,
and sometimes see patients with minor abnormalities in glucose
tolerance or just-discovered type-IT diabetes who have ad-
vanced renal or retinal disease. Glycemia is clearly a risk factor
but, as data from the Joslin Clinic and other centers have shown
[631, even the best-controlled patients are at risk, although at
low risk. In developing our hypothetical constructs, we need to
keep in mind the huge variability among the structural abnor-
malities among the end organs at risk in the same individual as
well as the variability in susceptibility among individuals. We
also must keep in mind that there are factors within families that
determine how this susceptibility works. Thus, although glyce-
mia-related abnormalities may be important, they do not ex-
plain the whole story. For example, the process of alteration of
molecules by glycosylation is presumably non-enzymatic and
related to the duration and magnitude of the hyperglycemia. It's
thus unlikely that glycosylation per se could explain everything.
At best it must be a partial explanation or must work through
intermediary steps that are themselves genetically regulated.
Similarly, the aldose reductase story, very much related to
glycemic control, could explain part but not all of the clinical
phenomena of diabetic complications. We need to better under-
stand the factors regulating the balance between matrix produc-
tion and matrix breakdown. Evidence in animals suggests that
overproduction might not be the key variable [64]. Matrix
breakdown in diabetes has received too little attention. The
factors that could be influencing the rate at which matrix
accumulates could include hemodynamic factors, growth fac-
tors, and other variables known to influence the rate at which
matrix is made and broken down. Very little specific informa-
tion is available. This is a wide open field for new work.
DR. MADIAS: I am interested in the changes in GBM collagen
that you described. I realize that these are still preliminary
observations, but how specific are those changes for diabetic
nephropathy as compared with other nephropathies?
DR. MAUER: In terms of immunochemical analysis by the
light microscopic method, they seem quite specific for diabetes
[191. The other disease that Dr. Youngki Kim in our group has
looked at carefully is membranous nephropathy, and there are
clear differences from diabetes [651. Not all of the new markers
for matrix proteins have been explored in all diseases, so it's
very early to be certain that the changes in diabetes are unique,
but currently this appears to be the case. In terms of electron
microscopic immunochemical studies, even less is known about
other renal diseases. Currently in our studies we are dividing
diabetic patients into "slow-" and "fast-track" for the devel-
opment of diabetic nephropathy lesions. The question being
asked is whether early on specific matrix abnormalities could
indicate whether an individual is at risk or safe from the later
development of progressive diabetic renal injury. The answer is
not yet available.
DR. JoHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): I'm interested in
your experience with serial biopsies in individual patients. In
what kind of patients have you done such studies, and what is
the rate of growth of the matrix portion of the mesangium?
DR. MAUER: To use serial biopsies to look at whether the rate
of development of lesions is linear in a given case, one needs 3
spaced biopsies. Two biopsies will not tell us whether the
lesions are linear over time, Our only experience so far is in the
renal allograft. It is easier to obtain biopsy tissue from the
transplanted kidney, and the baseline biopsy representing a
kidney never exposed to the diabetic state can be performed at
the time of transplant surgery. Our findings support the view
that the lesions develop linearly over time [66]. Our studies also
demonstrate marked variability in the rate of development of
matrix lesions between different individuals (unpublished data).
There are no carefully done studies at 3 time intervals in the
native kidney, however.
DR. MADIAs: There are now diabetic patients with microal-
buminuria who have been treated for several years with ACE
inhibitors and who have shown stabilization of the level of
microalbuminuria or return of albumin excretion to the normal
range. Does any information from baseline and followup biop-
sies on such patients allow structural-functional correlation?
Da. MAUER: Not that I know of.
DR. ANDREW S. LEVEY (Division of Nephrology, New En-
gland Medical Center): One potential way of separating glomer-
ular changes due to diabetes from changes due to nephropathy
is to examine insulin-dependent individuals who have had 20 to
40 years of diabetes but who have not developed nephropathy.
Have you examined the ultrastructural features of glomeruli
from these patients?
DR. MAUER: We find the longer the duration of diabetes, the
less is the correlation between duration and severity of the
lesion. What drives the relationship between duration and
severity is the fact that serious lesions are uncommon in the first
5 to 10 years. For example, with 30 years of diabetes, lesions
range from end-stage renal disease to virtually none. We've
studied 2 sisters—one with 55 years and the other with 45 years
of diabetes—whose kidney structures were still in the normal
range. Beyond 30 years of IDDM, one sees fewer individuals
with advanced lesions, because the people who are going to
develop nephropathy already have done so.
DR. LEVEY: It is certainly very interesting that some patients
with structural evidence of diabetic nephropathy have not yet
manifested abnormal urinary albumin excretion after 30 to 40
years.
Da. RICHARD LAFAYETTE (Division of Nephrology, New
England Medical Center): In your discussion regarding the
pathogenesis of albuminuria, you suggested that mesangial
expansion leads to changes in epithelial cell function and
membrane charge. Does the loss of membrane charge density
occur only in glomeruli with significant mesangial expansion, or
does it occur diffusely?
DR. MAUER: The glomeruli are remarkably uniform in dia-
betic nephropathy. Thus, morphometric analysis of 3 glomeruli
can show a correlation with GFR or with any other functional
measures. We measured charge site density only in the lamina
rara externa; we don't know what's going on in the other sites
such as the mesangium and other areas of the GBM. The
changes in the lamina rara externa charge-site density and in
epithelial cell structure seem to develop in parallel with rising
albumin excretion rates. Since lesions are generally well devel-
oped when UAE is substantially increased, these GBM charge-
site and epithelial changes occur relatively late in the process.
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The structural parameter that is strikingly disturbed, with less
overlap in patients who have versus those who do not have
high-level microalbuminuria than any other structural parame-
ter, is the reduction of relative filtration surface. One possibility
is that this loss of filtration surface provides a signal to the
glomerulus to alter its homeostasis, perhaps its internal hemo-
dynamics. There are other possibilities including growth fac-
tors, etc. However, it is possible that hemodynamic alterations
resulting from established lesions and reduction in filtration
surface could lead to changes in charge-site density and epithe-
hal cell structure and pore size. These latter changes could then
be either a consequence or a cause of altered glomerular
permeability. These thoughts are consistent with the idea that
improved glomerular hemodynamics induced by ACE inhibi-
tors reduce glomerular permeability in proteinuric [671 and
microalbuminuric [68] diabetic patients.
DR. JACK LEAHY (Endocrine Division, New England Medical
Center): I have two questions that might be naive, but they are
clinically based. Your work compares structure-function rela-
tionships. Clinically, we rarely perform biopsies on individuals
who have diabetes. In the second case that you presented, the
patient had microalbuminuria with already markedly abnormal
renal structure. Also, you describe people who didn't have any
proteinuria at all but who appear to have major structural
damage from diabetes. What role, if any, do biopsies play in
diagnosing or managing diabetic renal disease?
DR. MAUER: That is a difficult question. In part the answer
depends on what we can offer the patient as a consequence of
our examination. First, diabetologists tend to overestimate the
seriousness of the renal biopsy in terms of discomfort or risk.
Given current technology, it's a minor procedure. Second, let
me argue that from a nephrologist's point of view, the dominant
reasons for performing a renal biopsy are diagnosis and prog-
nosis. Only 20% to 25% of the time do the biopsies lead to a
therapeutic decision that would not have been made without the
biopsy. Third, other diseases such as systemic lupus erythema-
tosus (SLE) have a far lower risk of producing end-stage renal
failure. Further, renal disease in SLE is less associated with
excess mortality compared with renal disease in the type-I or
type-TI diabetic patients. Yet patients with SLE undergo renal
biopsy much more frequently than do people with diabetes.
Performing biopsies in diseases such as SLE has taught us
much about the natural history of the disease, and sometimes
we make treatment decisions based on these biopsies. Why do
we not biopsy the diabetic patients? Diabetic patients don't
develop clinical manifestations until late in the disease. As you
point out, the current evidence indicates that serious underlying
structural injury is often present before functional tests can
detect the damage. Unfortunately, in diabetic patients we do
not have the advantage of using markers of ongoing injury such
as microhematuria. In my view, the biopsy is not used enough
in diabetic patients. At the very least, if we could detect
patients developing serious lesions, we could offer the patient
improved glycemic control. Certainly we should use relatively
minor manifestations of renal disease, such as increasing albu-
min secretion (microalbuminuria) or changing blood pressure
(even if it's normal but increasing for that patient), as indicators
of serious underlying events. However, as I have pointed out,
some patients do not manifest these findings until structural
changes are relatively far advanced. In fact, some patients may
have a decline in GFR before microalbuminuria is manifest [69].
This tends to argue that we should be using the renal biopsy
more frequently since functional markers are imprecise. One
implication of your question is that without functional abnor-
malities, the structural lesions might not be important. How-
ever, serial biopsy studies (Fioretto P, unpublished data) indi-
cate that the lesions in normoalbuminuric patients with
structural abnormalities are progressive. The number-one cause
of renal failure in the Western world is diabetes, and we do have
therapeutic alternatives. We need to apply those alternatives to
the patients at risk and avoid their use in patients not at risk. We
currently don't have any way of selecting patients very early in
their course of developing important renal lesions except for the
renal biopsy, and we can't change the natural history of disease
to one that is more to our liking, that is, one with earlier
functional warnings of underlying structural changes. I argue
for a much closer relationship between diabetologists and
nephrologists. In the past, nephrologists have been restricted to
a functional evaluation of diabetic nephropathy even though,
like the eye, the function only deteriorates when it's too late.
Imagine asking ophthalmologists to limit themselves to func-
tional eye tests for diabetic retinopathy, precluding their look-
ing directly at the retinal vasculature that is being damaged.
Under these circumstances, would laser treatment of prolifer-
ative retinopathy have developed?
DR. LEAHY: I have great difficulty in understanding renal
disease in type-I versus type-Il diabetes. Clearly, these patients
manifest many similarities, but some striking dissimiiarities
also exist. How do you view the pathogenesis of the different
forms of diabetes?
DR. MAUER: Much less is known about type-Il for a number
of reasons. The risk of renal disease in type-TI diabetes is
probably not very different from that in type-I, but the age of
onset is so much later that many patients die of other causes in
the time frame required for them to develop renal disease. In
Pima Indians who develop type-IT diabetes at an earlier age, the
relationship between duration and risk of terminal uremia is
approximately the same as in type-I. In a couple of studies, 25%
of the proteinuria in type-Il diabetics results from another renal
disease [70, 71]. But the chance of finding other than diabetic
renal disease in a biopsy specimen from a proteinuric patient
who has had tyne-I diabetes for 10 years is only about 4%. Thus
if your patient has had IDDM for 10 years and has proteinuria,
you can have 95% certainty that diabetes is the cause of the
proteinuria. In type-TI, your certainty is down to 75%. If the
type-TI patient has retinopathy, the risk of error in diagnosis is
much lower [70]. Gambara and coworkers in Bergamo recently
published the description of a blending between glomerosclero-
sis and diabetic nephropathy in type-IT patients—not surprising
in that age population [72]. I would also speculate that this
combination of lesions might be why black people with type-IT
diabetes have a higher risk of end-stage renal disease compared
with whites, whereas in black people with type-I diabetes, that
is, the younger population, there is little or no increased risk
[73]. I imagine that the combination of hypertensive and dia-
betic nephropathy in the type-Il population is responsible for
the increase in risk among black people with type-TI diabetes.
Thus, in the type-Il patient, the causes of renal failure tend to
be more multifactorial: a higher incidence of other renal dis-
eases, more hypertensive nephropathy, and more effects of
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aging in addition to diabetic nephropathy. However, the major-
ity of type-IT patients developing clinical renal disease have
"garden variety" diabetic nephropathy.
DR. MADrAS: You mentioned that substantial evidence indi-
cates that IDDM patients with microalbuminuria or clinical
proteinuria feature an overactive Na/H exchanger in various
cells. Indeed, Dr. Viberti and colleagues have shown that in
normotensive, normo- or microalbuminuric IDDM patients,
increased red blood cell Na/Li CTT activity was associated
with reduced insulin sensitivity, left-ventricular hypertrophy,
and lipid disturbances [74]. I am particularly fascinated by the
findings of a study by Can et al in normotensive and normoal-
buminuric IDDM patients: 33% of these patients had increased
red blood cell Na/Li Cr1' activity and were the very same
patients who featured hyperfiltration and increased filtration
fraction compared with IDDM patients without elevated activ-
ity versus control subjects [75]. The authors speculated that
increased activity of this transporter might identify IDDM
patients destined to develop essential hypertension and diabetic
nephropathy; this concept has potentially tremendous clinical
implications. Do you have any data on the activity of the
Na/H exchanger in that subgroup of IDDM patients you
mentioned who have normal albumin excretion but elevated
blood pressure? Also, is there any information correlating
activity of the Na/H exchanger with renal histology in
normoalbuminuric individuals?
DR. MAUER: Not that I know of. Regarding the hypertensive
normoalbuniinui-jc patients, Dr. Paola Fioretto and the group in
Padova led by Dr. Romano Nosadini has shown that diabetic
hypertensive patients with normal red blood cell Na/Li CTT
activity tend to have normal albumin execretion rates [76].
Also, work from the Padova group confirmed that Na/H
antiport and red blood cell Na/Li CTT are functional modes
of the same transporter in type-I diabetic patients [77]. How-
ever, studies have not been designed specifically to answer this
question, and hypertensive normoalbuminuric patients with
IDDM are relatively rare. There is currently inadequate work
done to answer your question regarding Na'7H exchanger
activity and renal histology in normoalbuminuric patients. Dr.
Lurbe in Dr. Batlle's group in Chicago working with Dr.
Fioretto and our group showed that normoalbuminuric type-I
diabetic patients have normal cultured fibroblast Na/H ex-
changer activity, and had, as expected, less serious renal
lesions than did a proteinuric group of patients [78]. However,
at present there is insufficient information to determine whether
raised Na/H exchanger activity in normoalbuminuric pa-
tients predicts worse underlying nephropathology or a worse
prognosis.
DR. ANDREW KING (Division of Nephrology, New England
Medical Center): Several inherited factors have been postulated
to increase the risk of progression of renal disease. Recently, it
has been postulated that nephron number is one such factor
[79]. In this regard, does the rate of progression in a diabetic
patient predict the rate of progression alter transplantation in
the same patient?
DR. MAUER: No, it does not. We looked at the regression
analysis of the number of years of type-I diabetes to end-stage
renal failure and the rate of development of changes of diabetes
in the renal allograft, and there was no relationship whatsoever
[66].
DR. JosE C. TEIxEut DA SILVA (Fellow in Nephrology,
Boston University Medical Center, Boston): A recent publica-
tion by Hogan et al shows that advanced glycosylation end
products quenching nitric oxide decrease the antiproliferative
effect of the latter on mesangial cells [80]. What would be the
impact on the progression of diabetic nephrosclerosis? Is pro-
liferation of mesangial cells a factor of mesangial matrix expan-
sion and sclerosis?
DR. MAUER: Let me make a couple of points in this regard.
We have no clear evidence yet that mesangial cell proliferation
is a component of diabetic nephropathy. The bulk of mesangial
expansion in diabetes is matrix and not cell [27]. Cell number
has never been carefully enumerated; it's extremely difficult to
do, even at the electron microscopic level. On a given section,
a skilled individual will mistake endothelial cells for mesangial
cells 20% to 30% of the time. You have to do serial sections to
enumerate mesangial cells; otherwise it's not an accurate mea-
sure. So there is no clear evidence yet that mesangial cell
proliferation out of proportion to the increase in glomerular
volume is a component of diabetic nephropathy. Second, I can't
comment much on the relationship between the nitric oxide and
glycosylation except to say that we have renal physiologic data
in animals suggesting that the nitric oxide system might be
overactive rather than underactive in the diabetic rat kidney
[81]. We need to do a lot more work to determine the role of the
nitric oxide system in the kidney in diabetes both in terms of
renal hemodynamics and in terms of cell proliferation and
matrix dynamics.
DR. HARRINGTON: If you take a kidney from a diabetic
animal and transplant it into a nondiabetic animal, does the
disease resolve and, if so, over what time period?
DR. MAUER: We did that back in 1975. Using light micro-
scopic studies, we put normal kidneys into diabetic rats and
found that the lesions developed. We then took kidneys that
had been in the diabetic environment for 6 or 7 months and
transplanted them into normal rats, and we found regression of
the lesions within 2 months [82].
DR. MADIAs: What kind of rats did you use?
DR. MAUER: These were highly inbred Lewis rats, so rejec-
tion of the kidney was avoided. However, when patients with
15 to 20 years of diabetes and well-established lesions are cured
of diabetes with a successful pancreas transplant, the renal
lesions do not improve over the next 5 years [83]. Whether this
means early lesions are reversible while late lesions are not, or
that rat and human lesions are inherently different, is not
known.
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